2017
“What if I do nothing?” The natural history of operable cancer of the alimentary tract
Keshava HB, Rosen JE, DeLuzio MR, Kim AW, Detterbeck FC, Boffa DJ. “What if I do nothing?” The natural history of operable cancer of the alimentary tract. European Journal Of Surgical Oncology 2017, 43: 788-795. PMID: 28131669, DOI: 10.1016/j.ejso.2016.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Signet Ring CellCarcinoma, Squamous CellColonic NeoplasmsDatabases, FactualDisease ProgressionEsophageal NeoplasmsFemaleGastrointestinal NeoplasmsHumansMaleMiddle AgedNeoplasm StagingRectal NeoplasmsStomach NeoplasmsSurvival RateUnited StatesWatchful WaitingConceptsAlimentary tract cancersTract cancerNatural historyUntreated patientsCancer surgeryClinical stage IStage-specific survivalOperable cancerInoperable patientsMedian survivalRectal cancerClinical stagePreoperative counselingPatientsStage ISurgeryCancerPoor healthAlimentary tractSurvivalHealth reasonsStudy objectiveTreatmentCIICIII
2016
The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database
Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2016, 101: 1850-1855. PMID: 27041452, DOI: 10.1016/j.athoracsur.2016.01.077.Peer-Reviewed Original ResearchConceptsOperable non-small cell lung cancerNon-small cell lung cancerNational Cancer DatabaseUntreated NSCLC patientsClinical stage ICell lung cancerNSCLC patientsNatural historyStage ILung cancerCancer DatabaseUntreated non-small cell lung cancerIIIA non-small cell lung cancerMultivariable Cox regression modelsLarge cell histologyNatural history cohortOperable NSCLC patientsCox regression modelMedian survivalUntreated patientsCell histologyMeier estimatesSurgical resectionClinical stageSquamous cells
2015
Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients – A systematic review
DeLuzio MR, Moores C, Dhamija A, Wang Z, Cha C, Boffa DJ, Detterbeck FC, Kim AW. Resection of oligometastatic lung cancer to the pancreas may yield a survival benefit in select patients – A systematic review. Pancreatology 2015, 15: 456-462. PMID: 25900320, DOI: 10.1016/j.pan.2015.03.014.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOligometastatic lung cancerCurative-intent resectionLung cancerSystematic reviewMedian survivalSurvival benefitPancreatic metastasisPrimary lung malignancyOverall median survivalSignificant survival benefitCox regression analysisCell lung cancerMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsSurveillance CTPalliative surgeryMetachronous presentationPancreatic headSelect patientsSurgical therapyLung malignancyKaplan-MeierPatientsReporting Items
2012
Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry
Ahmad U, Wang Z, Bryant AS, Kim AW, Kukreja J, Mason DP, Bermudez CA, Detterbeck FC, Boffa DJ. Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry. The Annals Of Thoracic Surgery 2012, 94: 935-941. PMID: 22835555, DOI: 10.1016/j.athoracsur.2012.04.069.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Bronchiolo-AlveolarAdultAnalysis of VarianceCause of DeathDisease-Free SurvivalFemaleGraft RejectionGraft SurvivalHospital MortalityHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsLung TransplantationMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPatient SelectionPreoperative CarePrognosisProportional Hazards ModelsRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTissue and Organ ProcurementTreatment OutcomeConceptsLung transplantationBronchoalveolar carcinomaLung transplantUnited NetworkLung cancerDouble lung transplantOrgan Sharing databaseOrgan Sharing registrySubgroup of patientsMaximum survival advantageBAC patientsSecond percentExpiratory volumeMedian survivalTransplantation cohortSharing databasePoor prognosisPure adenocarcinomaPathology reportsInvasive tumorsSurvival advantageExtended survivalTransplantationPatientsTransplant
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2008
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival